

Investor Presentation Financial Year 2013/14




This document has been prepared as a summary only, and does not contain all information about the Company's assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company's securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by SomnoMed Limited. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the Shares or that there will be an increase in the value of the Shares in the future. Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company's operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as "aim", "could", "estimate", "expect", "intend", "target", "forecast", "future", "will", "may", "potential", "should" and similar expressions are forward-looking statements.

Although the company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company's published material. Many of these factors are beyond the control of SomnoMed Limited and may involve subjective judgement and assumptions as to future events, which may or may not be correct.

The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.


Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.






Unit sales growth

Revenue growth (\$' millions)






APAC quarterly unit sales






USA quarterly unit sales






Europe quarterly unit sales





Somnol Med The Leader In COAT

(Continuous Open Airway Therapy)



Share of units sold by global region

Financial Summary (\$000's)	08/09	09/10	10/11	11/12	12/13	13/14
Revenue	7,737	10,714	12,335	15,246	18,489	25,894
Net Average Sales Per Unit (Direct MAS – Actual \$)	641	562	536	535	562	639
Gross Margin Group Gross Margin % MAS Gross Margin %	4,059 52.5% 55.2%	6,084 56.8% 59.3%	8,176 66.3% 68.0%	10,357 67.9% 70.1%	12,267 66.3% 69.3%	16,810 65.0% 67.0%
Sales and Marketing, G&A expenses	4,040	4,241	5,114	7,077	9,040	13,112
Operating profit before corporate, research and development expenses, non cash items and income tax	19	1,843	3,062	3,280	3,227	3,698
Corporate expenses Share of associated company profits other	(1,176) –	(1,769) 216	(2,303) 232	(2,356) 158	(2,460) 63	(2,648) –
EBITDA*	(1,767)	290	991	1,082	830	1,050

*EBITDA as adjusted; does not include share and option expense.





	2013/14				
Financial Summary (\$000's) Underlying EBITDA*	Total Year	1st Half	2nd Half		
Revenues	25,894	12,553	13,341		
Investments made in FY14:					
Investments in Medical Capabilities (MAB, CMO, Managed Care, Medical Sales Team) USA	1,850	915	935		
Acquisition & Legal costs Europe	108	62	46		
New market set-up, legal and recruitment costs	325	-	325		
Total Investments made	2,283	977	1,306		
Posted EBITDA*	1,050	680	370		
Underlying EBITDA*	3,333	1,657	1,676		
% Revenues	12.9%	13.2%	12.6%		

*EBITDA as adjusted; does not include share and option expense.




Financial Summary Net profit after taxation		2012/13	2013/14
Operating profit before corporate, research and business development expenses, non cash items and income tax		3,227,060	3,697,689
Share of profit of associated company		63,601	-
Corporate, research and business development expenses		(2,460,722)	(2,648,325)
Revenue from investment activities		92,819	26,438
Share and option expense		(88,183)	(125,003)
Depreciation and amortisation		(503,283)	(626,143)
Interest expense		-	(12,748)
Unrealised foreign exchange loss		(16,305)	(81,417)
Profit before income tax expense		314,987	230,491
Income tax benefit/(expense)	lote 1	389,688	(15,535)
Profit after income tax for the year		704,675	214,956


Note 1		
Tax paid	(290,694)	(318,545)
Deferred tax adjustments	680,382	303,010
Income tax benefit/(expense)	389,688	(15,535)



Unit sales to grow by 26.5% in 2014/15 to 55,000 units



Revenue to grow by 25% in 2014/15 to \$32.5M*



*constant exchange rates



SomnoMed Guidance 2014/15

Demand for custom made oral appliances as alternative treatment for sleep disordered breathing is expanding worldwide

- Increased awareness of sleep disordered breathing and simpler home sleep testing drive number of diagnosed patients
- More clinical research uncovering the link between OSA and other severe medical conditions and mortality
- Persistent rejection and non-compliance of CPAP remains a growing issue for physicians, insurers and patients
- Increasing confidence of efficacy of COAT[™] especially as higher compliance is linked to patient comfort
- Increasing awareness of COAT[™] delivering a lower treatment costs than CPAP over the treatment term

- Different countries adopt COAT[™] at different speeds but the share of patients is growing world wide:
 - Sweden 52% COAT™ and 48% CPAP (2013)¹
 - Holland 45% COAT™ and 55% CPAP (2013)²
 - USA 5% COAT™ and 95% CPAP (2013)³
- According to Frost and Sullivan Report, the US market will grow from 180,000 - 200,000 patients fitted with a custom made oral appliance in 2013 to over 1 million patients in 2020³

¹ Swedish National Health Department Reimbursement statistics

² Netherlands Health Department Reimbursement statistics

³ Frost & Sullivan, Assessment of the US Oral Appliances for Sleep Apnea Market, June 2014 – based on a projected growth of value of Custom Made Oral Appliance market from \$63M in 2013 to \$343M in 2020 and assumed net average sales prices in different price segments.





Growth Driver 2

Broadening the SomnoDent® product line

Flex		SomnoDent Flex			SomnoDent G2		SomnoDent Herbst	SomnoDent Fusion ¹ SomnoDent Herbst Advance ¹	NEW
Standard	SomnoDent Classic						SomnoDent Herbst	SomnoDent Herbst Advance ¹	NEW
Other								SomnoDent Compliance Control ³	
	2007	2008	2009	2010	2011	2012	2013	2014	2015

¹ Launch September 2014

² Launch August 2014

³ Launch September 2014 (Europe/APAC) and June 2015 (USA – Subject to FDA)



Entry into new markets

Established Markets Entry 2004 - 2008	Emerging Markets Entry 2009 - 2013	New Markets Entry 2014 - 2015
Asia-Pacific	Asia-Pacific	Asia-Pacific
Australia	New Zealand (2009) Japan (2009) Singapore (2010)* Malaysia (2010)* Indonesia (2010)* Korea (2010)* Israel (2010)*	Korea (2014)
North Amercia	North Amercia	North Amercia
USA Canada		
Еигоре	Europe	Еигоре
Sweden* Germany* Holland* Italy* Switzerland*	Holland (2012) France (2013) Sweden (2013) Germany (2013) Austria (2013) Norway (2013) Belgium (2013) Luxembourg (2013) Russia (2013) Denmark (2013)	Finland (2014) United Kingdom (2014) Republic of Ireland (2014) Spain (2014) Portugal (2014) Italy (2014)
		*Th






SomnoMed Guidance 2014/15

Profits to double in 2014/15 - EBITDA* range of \$2.0 to \$4.0 Million

- The financial year 2014/15 will start to show the earnings strength of SomnoMed
- After investing approximately \$2m in FY14 in building the base for medical in USA, this division will break even in 2014/15
- New market entries in Europe are expected to break even in Second Half 2014/15
- Gross margin to be maintained in the high sixty percent range:
 - economies of scale impact on COGS manufacturing, freight, national service centres
 - phasing in of digital will reduce freight and production costs
 - stable corporate overheads despite growth in volume



EBITDA* Guidance 2014/15





Executive Chairman and CEO Chief Financial Officer Address

Telephone Website Dr Peter Neustadt Mr Neil Verdal–Austin Level 3 20 Clarke Street Crows Nest NSW 2065 Australia +61 (2) 9467 0400 www.somnomed.com.au



